drugset / Trial / NCT05376839
A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment
Non-randomizedSequentialOpen-labelTreatment
Summary
The objective of this study is to evaluate the pharmacokinetics and safety of cedirogant following oral administration of multiple doses in adult participants with hepatic impairment and normal hepatic function.
Timeline
- Start
- 2022-07-06
- Primary completion
- 2022-11-08
- Completion
- 2022-11-08
Outcome
Outcome not reported
Stopped (Business): “Strategic considerations”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cedirogant | Small molecule | — | Oral |
Indications
No indication recorded.